In late September, FDA moved toward label changes and issued a physician notice on possible neurodevelopment associations, even as ACOG reaffirmed acetaminophen’s role in pregnancy, fueling confusion, press attention, and new plaintiff messaging. Meanwhile, the Second Circuit reset argument timing and state courts remain a live venue. Corporate and trial teams need a clear playbook before year-end.
In this workshop, session leaders will walk you through:
- Litigation background and the current status of disputes over science and general causation
- Tracking Second Circuit proceedings and the potential impact on future proceedings in federal court and elsewhere
- Pressure-testing general-causation theories and stress-testing the parties’ respective expert opinions
- Assessing FDA, HHS, and administration statements for labeling, warning, and preemption exposure—and scenario-planning for potential changes
- Coordinating manufacturer–retailer defenses and aligning notice, warnings, and supply-chain documentation in a fast-moving media cycle
- Preparing corporate communications and medical-affairs responses for renewed public scrutiny and investor questions
- Benchmarking settlement posture, removal/transfer tactics, and bellwether considerations if filings accelerate
- Perception of the current Administration and corresponding effects on potential jury candidate pools
- Evaluating the effects of juror sentiment toward federal policy makers
- Anticipating the impact on causation and damages narratives
